Medifast Competitors

Coca-Cola FEMSA (NYSE:KOF) and Medifast (NYSE:MED) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Dividends

Coca-Cola FEMSA pays an annual dividend of $2.31 per share and has a dividend yield of 4.7%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Coca-Cola FEMSA pays out 77.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast has raised its dividend for 1 consecutive years. Coca-Cola FEMSA is clearly the better dividend stock, given its higher yield and lower payout ratio.

Valuation & Earnings

This table compares Coca-Cola FEMSA and Medifast's gross revenue, earnings per share (EPS) and valuation.

Coca-Cola FEMSA has higher revenue and earnings than Medifast. Coca-Cola FEMSA is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

8.4% of Coca-Cola FEMSA shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 1.0% of Coca-Cola FEMSA shares are held by company insiders. Comparatively, 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Coca-Cola FEMSA and Medifast, as provided by MarketBeat.com.

Coca-Cola FEMSA currently has a consensus price target of $50.00, suggesting a potential upside of 3.26%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Coca-Cola FEMSA.

Profitability

This table compares Coca-Cola FEMSA and Medifast's net margins, return on equity and return on assets.

Volatility and Risk

Coca-Cola FEMSA has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Medifast beats Coca-Cola FEMSA on 13 of the 17 factors compared between the two stocks.

Aramark (NYSE:ARMK) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Dividends

Aramark pays an annual dividend of $0.44 per share and has a dividend yield of 1.1%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Aramark pays out -258.8% of its earnings in the form of a dividend. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Aramark has raised its dividend for 1 consecutive years and Medifast has raised its dividend for 1 consecutive years.

Valuation & Earnings

This table compares Aramark and Medifast's gross revenue, earnings per share (EPS) and valuation.

Medifast has lower revenue, but higher earnings than Aramark. Aramark is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

93.5% of Aramark shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 10.3% of Aramark shares are held by company insiders. Comparatively, 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Aramark and Medifast, as provided by MarketBeat.com.

Aramark currently has a consensus price target of $32.3077, suggesting a potential downside of 16.43%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Aramark.

Profitability

This table compares Aramark and Medifast's net margins, return on equity and return on assets.

Volatility and Risk

Aramark has a beta of 1.88, suggesting that its stock price is 88% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, suggesting that its stock price is 52% more volatile than the S&P 500.

Summary

Medifast beats Aramark on 10 of the 16 factors compared between the two stocks.

Albertsons Companies (NYSE:ACI) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, institutional ownership and analyst recommendations.

Valuation & Earnings

This table compares Albertsons Companies and Medifast's gross revenue, earnings per share (EPS) and valuation.

Albertsons Companies has higher revenue and earnings than Medifast.

Insider and Institutional Ownership

40.6% of Albertsons Companies shares are held by institutional investors. Comparatively, 83.0% of Medifast shares are held by institutional investors. 4.0% of Medifast shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Dividends

Albertsons Companies pays an annual dividend of $0.40 per share and has a dividend yield of 2.0%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Medifast has raised its dividend for 1 consecutive years. Medifast is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Albertsons Companies and Medifast's net margins, return on equity and return on assets.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Albertsons Companies and Medifast, as provided by MarketBeat.com.

Albertsons Companies currently has a consensus price target of $19.75, suggesting a potential downside of 0.20%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts clearly believe Medifast is more favorable than Albertsons Companies.

Summary

Medifast beats Albertsons Companies on 9 of the 14 factors compared between the two stocks.

Service Co. International (NYSE:SCI) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Valuation and Earnings

This table compares Service Co. International and Medifast's gross revenue, earnings per share (EPS) and valuation.

Service Co. International has higher revenue and earnings than Medifast. Service Co. International is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

83.4% of Service Co. International shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 4.7% of Service Co. International shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

Service Co. International has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500.

Dividends

Service Co. International pays an annual dividend of $0.84 per share and has a dividend yield of 1.6%. Medifast pays an annual dividend of $5.68 per share and has a dividend yield of 2.4%. Service Co. International pays out 44.2% of its earnings in the form of a dividend. Medifast pays out 95.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Service Co. International has raised its dividend for 1 consecutive years and Medifast has raised its dividend for 1 consecutive years.

Profitability

This table compares Service Co. International and Medifast's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Service Co. International and Medifast, as provided by MarketBeat.

Service Co. International currently has a consensus price target of $49.25, suggesting a potential downside of 5.01%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's higher possible upside, analysts plainly believe Medifast is more favorable than Service Co. International.

Summary

Medifast beats Service Co. International on 8 of the 15 factors compared between the two stocks.

US Foods (NYSE:USFD) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares US Foods and Medifast's gross revenue, earnings per share and valuation.

US Foods has higher revenue and earnings than Medifast. US Foods is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

88.8% of US Foods shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 1.0% of US Foods shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

US Foods has a beta of 1.8, indicating that its stock price is 80% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares US Foods and Medifast's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for US Foods and Medifast, as provided by MarketBeat.

US Foods currently has a consensus price target of $40.10, suggesting a potential upside of 3.38%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than US Foods.

Summary

Medifast beats US Foods on 9 of the 14 factors compared between the two stocks.

Beyond Meat (NASDAQ:BYND) and Medifast (NYSE:MED) are both mid-cap consumer staples companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, analyst recommendations and valuation.

Earnings and Valuation

This table compares Beyond Meat and Medifast's gross revenue, earnings per share and valuation.

Medifast has higher revenue and earnings than Beyond Meat. Beyond Meat is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

42.1% of Beyond Meat shares are owned by institutional investors. Comparatively, 83.0% of Medifast shares are owned by institutional investors. 11.0% of Beyond Meat shares are owned by company insiders. Comparatively, 4.0% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Beyond Meat has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Medifast has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.

Profitability

This table compares Beyond Meat and Medifast's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent ratings for Beyond Meat and Medifast, as provided by MarketBeat.

Beyond Meat currently has a consensus price target of $121.1111, suggesting a potential downside of 8.76%. Medifast has a consensus price target of $292.3333, suggesting a potential upside of 23.86%. Given Medifast's stronger consensus rating and higher possible upside, analysts plainly believe Medifast is more favorable than Beyond Meat.

Summary

Medifast beats Beyond Meat on 10 of the 13 factors compared between the two stocks.